The global vaccines market is estimated at $41bn in 2018 and is expected to grow at a CAGR of 10.9% during the forecast period. The Paediatric Vaccines segment held 56% of the Global Vaccines market in 2018.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 201-page report you will receive 121 charts– all unavailable elsewhere.
The 201-page report provides clear detailed insight into the global vaccines sales market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Vaccines Sales Market forecasts from 2019-2029
• Global Vaccines Sales Market forecasts from 2019-2029 by Submarket: • Paediatric Vaccines • Adult Vaccines • Elderly Vaccines • Travel Vaccines • Therapeutic Vaccines
• Global Vaccines Sales Market forecasts from 2019-2029 by Leading Vaccines: • Prevnar • Gardasil • Fluzone • Pentacel • ProQuad • Infanrix/Pediarix • Zostavax • RotaTeq • Hepatitis Vaccines • Menactra
• Global Vaccines Sales Market forecasts from 2019-2029 by Regional and National Market: • US • EU5: Germany, France, Italy, UK, Spain • Japan • Brazil • Russia • India • China
• Profiles of the selected leading companies: • AstraZeneca • Eli Lilly • Emergent BioSolutions Inc. • GlaxoSmithKline • Johnson & Johnson • Merck & Co. • Pfizer • Sanofi • Serum Indian Institute Pvt. Ltd. • Takeda
• The Vaccines Market Pipeline Analysis
• A SWOT and STEP analysis of the global vaccines market
• Key Questions Answered by this Report: • What is the current size of the overall global human vaccines market? How much will this market be worth from 2018 to 2029? • What are the main drivers and restraints that will shape the overall vaccines market over the next ten years? • What are the main segments within the overall human vaccines market? How much will each of these segments be worth for the period 2018 to 2029? How will the composition of the market change during that time, and why? • What factors will affect that industry and market over the next ten years? • What are the largest national markets for the world vaccines? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2028? • How will political and regulatory forces influence regional markets? • How will market shares of the leading national markets change by 2029, and which geographical region will lead the market in 2029? • Who are the leading companies and what are their activities, results, developments and prospects? • What are the leading vaccines? What are their revenues and latest developments? • What are some of the most prominent human vaccines currently in development? • What are the main trends that will affect the world vaccines market between 2018 and 2029? • What are the main strengths, weaknesses, opportunities and threats for the market? • What are the social, technological, economic and political influences that will shape that industry over the next ten years? • How will the global vaccines market evolve over the forecasted period, 2018 to 2029? • How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029? • Which therapies can succeed and what revenues could they generate to 2029? • What will be the main commercial drivers for the market from 2018 to 2029? • How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth? • How will that industry evolve between 2018 and 2029, especially in R&D?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Vaccines Sales Market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Overview of the World Vaccines Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to the World Human Vaccines Market
2.1 Human Vaccines - Aiming for Global Disease Prevention
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.
The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.
Visiongain Publishes Human Microbiome Market Report 2023-2033
The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
